Market closed · data as of 27 Aug 2026 · source NSE via Alphave. Open the live chart →
Pfizer Ltd is the listed Indian subsidiary of Pfizer Inc., marketing prescription pharmaceuticals in India across vaccines (Prevenar 13 pneumococcal vaccine, a key brand), anti-infectives (Magnex), pain/inflammation, and legacy brands such as Becosules (multivitamin), Corex family and Gelusil. It operates a lean model with significant outsourced manufacturing and focuses on high-equity brands rather than volume generics. Growth depends on parent-portfolio launches and key brand traction in the Indian private market.
It is one of the larger MNC pharma subsidiaries listed in India, with Becosules and Prevenar among the country's top pharma brands.
Pfizer Ltd. is a constituent of NIFTY 500, NIFTY SMALLCAP 250. See where it sits on the market heatmap →
Consolidated annual figures taken from Pfizer Ltd.'s own filed statements — not estimates, and not restated by us. The most recent period shown is FY26 (year ended 31 Mar 2026).
| Metric | FY26 | FY25 | FY24 |
|---|---|---|---|
| Return on equity | 17.2% | 18.2% | 15.3% |
| Return on capital employed | 19.7% | 15.7% | 15.6% |
| Operating margin | 33.6% | 29.8% | 26.1% |
| Net margin | 28.7% | 33.6% | 25.1% |
| EBITDA | ₹904 Cr | ₹740 Cr | ₹635 Cr |
| Free cash flow | ₹942 Cr | ₹632 Cr | ₹238 Cr |
| Total debt | ₹3 Cr | ₹3 Cr | ₹3 Cr |
| Debt to equity | 0.00 | 0.00 | 0.00 |
| Interest coverage | 89.3 | 80.8 | 37.2 |
| Current ratio | 6.06 | 6.17 | 5.01 |
Open the full income statement, balance sheet and cash flow for PFIZER →
As disclosed for the quarter ended 30 Jun 2026.
Institutional ownership changes quarter to quarter. See daily FII and DII flows across the market →
Companies Alphave classifies in the same sub-sector, closest by market capitalisation.